Submission of outcome of the Board meeting held on 11th December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Novelix Pharmaceuticals Ltd (formerly Trimurthi Limited) on 11th December 2025 approved a preferential issue of 25,00,000 (25 lakh) equity shares at Rs. 60 per share, with a face value of Rs. 10 and a premium of Rs. 50 per share, totaling Rs. 15 crore. The shares will be allotted to 40 allottees, including promoters, promoter group members, and non-promoters, subject to shareholder approval at an Extra Ordinary General Meeting (EGM) scheduled for 9th January 2026. This capital raise is being done under Sections 42 and 62 of the Companies Act and SEBI's ICDR Regulations to raise additional capital. An EGM notice has been approved, and a scrutinizer has been appointed for the e-voting process, with the cut-off date set as 2nd January 2026.
This preferential allotment will dilute existing shareholders by issuing new equity at a significant premium, bringing in Rs. 15 crore of fresh capital. Existing public shareholders should monitor the EGM on 9th January 2026, as their approval is required for the issue to proceed.